Tenet beats on revenue growth
Considering the conpany's fundamentals, Zacks maintains a long-term 'outperform' recommendation on this stock.
By Zacks Equity Research
Tenet Healthcare Corp. (THC) reported second-quarter income from continuing operations of 10 cents per share, surpassing the Zacks Consensus Estimate of 5 cents, as well as the prior-year quarter’s earnings of 8 cents.
Operating income for the quarter inched up to $42 million from $40 million recorded a year earlier.
Growth in revenue arising from higher adjusted admissions, outpatient visits and surgeries led to the year-over-year improvement in earnings. However, the growth was partially offset by the rising operating expenses.
Considering post-tax impairment and restructuring charges of $50 million ($100 million pre-tax), or 12 cents per share, related to the anticipated sale of the Creighton University Medical Center, net loss came in at $6 million or 1 cent per share versus net income of $55 million or 11 cents per share a year earlier.
Operational Update
Net operating revenue stood at $2.27 billion, up 6.2% from $2.13 billion in the prior-year quarter. However, reported revenue lagged the Zacks consensus estimate of $2.48 billion.
During the reported quarter, Tenet’s net patient revenues per adjusted patient day increased 5.3% on a year-over-year basis to $2,543, primarily due to improved terms of commercial managed care contracts, partially offset by an adverse shift in payer mix.
Admissions edged down 0.4% during the quarter, while adjusted admissions climbed 1.5% year over year. Surgeries increased 4.9% and emergency department visits improved 5.0%.
Bad debt expense increased 13.1% to $190 million from $168 million in the second quarter of 2011.
Tenet posted adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $288 million in the reported quarter, up 4.7% from $275 million in the prior-year quarter. Adjusted EBITDA for the year-ago quarter includes Health Information Technology incentive payment of $25 million. Adjusted EBITDA margin was 12.7% compared with 12.9% in the year-ago quarter.
Financial Position
Tenet exited the quarter with $82 million in cash, down from $104 million as of March 31. As of June 30, total assets were $8.49 billion and shareholders’ equity was $1.18 billion.
Net cash flow from operating activities in the reported quarter was $243 million, soaring from $178 million in the year-ago quarter. Tenet’s capital expenditures increased to $116 million in the quarter, compared with $82 million in the prior-year quarter.
Guidance
Tenet affirmed its adjusted EBITDA guidance of $1.250 billion to $1.375 billion for 2012. Net operating revenues are expected to be about $9 billion to 9.3 billion, while operating income is projected to be about $235 million to $317 million.
Additionally, shares outstanding as of Dec. 31, 2012 are expected to be approximately 437 million. Consequently, earnings per share for 2012 are expected to be about 54 cents to 73 cents. Further, net income is anticipated to be around $165 million to $270 million.
Peer Take
Universal Health Services (UHS), a rival of Tenet, declared its second-quarter earnings of $1.12 per share, beating both the Zacks Consensus Estimate of $1.11 and the year-ago earnings of $1.04.
Another competitor, HCA Holdings (HCA), reported adjusted income of 85 cents per share in the second quarter of 2012, surpassing the Zacks Consensus estimate of 78 cents and the year-ago earnings of 51 cents.
Zacks Rank
Tenet carries a Zacks No. 2 Rank, implying a short-term "buy" rating. Considering the fundamentals, we maintain our long-term "outperform" recommendation on the shares.
More from Zacks
MORE ON MSN MONEY
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
LATEST POSTS
Liquidity infusions are not what they appear to be as actual and perceived liquidity can vary greatly.
FIDELITY VIEWPOINTS
- How to sell covered calls - Fidelity Investments
- Savvy year-end tax moves to consider now - Fidelity Investments
- Seven ways to prepare for tax changes
- Five reasons an annual review is crucial - Fidelity Investments
- Take a look at mid caps now - Fidelity Investments
- State of the sector: Health care - Fidelity Investments
VIDEO ON MSN MONEY
ABOUT
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
